Indivior PLC - Director Declaration
Indivior PLC confirms that Daniel Tassé, Senior Independent Director, will be appointed Chief Executive Officer of DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical stage biopharmaceutical company, with effect from November 29, 2018.
There have been no other changes to the information set out in LR 9.6.13R (2) to LR 9.6.13R (6) in respect of Mr Tassé.
This announcement is made in accordance with Listing Rule 9.6.14.
Kathryn Hudson
Company Secretary